PRESS RELEASE
  • by : Bill Faloon
NEW

The FDA Holocaust Museum was established in 1994 at a South Florida storefront and received international recognition.

The purpose was to expose human atrocities committed by an FDA that had grown increasingly incompetent and corrupt.

The Museum exposed the FDA’s sordid history of approving dangerous drugs, while denying access to lifesaving drugs, healthier foods, and dietary supplements supported by peer-reviewed scientific studies.

The FDA Holocaust Museum  was resurrected in 2019 and is based in Las Vegas, Nevada today.

Delaying the Approval of Life Saving Medicines

FDA desperately needs an overhaul

by Brian Blase  May 09, 2020 06:47 PM  The Food and Drug Administration, along with the Centers for Disease Control and Prevention, failed America with its

Read More »

 FDA Murder of 500,000 Americans

The public is now aware of the opioid drug crisis that has destroyed millions of lives and killed over 500,000 Americans. What few people know is that corrupt FDA officials approved OxyContin® in 1995 and allowed it to be sold as “less prone to addiction and abuse” than other opioids like heroin. FDA officials responsible for approving this synthetic heroin drug then went to work for the very company (Purdue Pharma) that reaped $billions of profits that ignited today’s carnage of addiction, overdoses, and deaths. In 2001, FDA went further and allowed powerful opioid drugs to be marketed as effective for “daily, around-the-clock, long-term… treatment”. This “approval” fueled wider prescribing of opioids in higher doses. Put simply, had FDA recognized that any form of heroin is highly addictive, today’s opioid carnage would not have occurred.

Dr. Andrew Kolodny:

We found out that a group of experts and FDA and pharmaceutical companies were having private meetings and at these meetings, changing the rules for how opioids get approved.:

In email after email between the FDA, Big Pharma and consultants, he learned of closed-door meetings at luxury hotels, like this Four Seasons in Washington, DC, where for $35,000 a piece, drug makers paid consultants to, “sit at a small table with the FDA,” “hobnobbing with the regulators.” Emails show one participant worrying it might be seen as “pay to play.”

They had drugs in their pipeline, pain medicines that they wanted approved. And through these meetings, they were able to get those products on the market.

Equally suspicious but legal, the large number of key FDA regulators who went through the revolving door to jobs with drug manufacturers. The two medical officers, who originally approved Oxycontin, Curtis Wright and Douglas Kramer, went to work for the opioid maker, Purdue Pharma, not long after leaving the FDA.